Xencor (NASDAQ:XNCR) Reaches New 1-Year Low - Time to Sell?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.55 and last traded at $10.81, with a volume of 165586 shares. The stock had previously closed at $11.23.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company dropped their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. StockNews.com downgraded Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $34.38.

Xencor Price Performance

The stock has a market capitalization of $628.52 million, a P/E ratio of -2.79 and a beta of 0.90. The business has a fifty day simple moving average of $14.73 and a 200 day simple moving average of $19.78. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.19. The business had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. On average, analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Remove Ads

Institutional Trading of Xencor

Institutional investors and hedge funds have recently made changes to their positions in the company. Intech Investment Management LLC bought a new stake in Xencor in the 3rd quarter worth about $368,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Xencor by 7.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company's stock valued at $12,609,000 after acquiring an additional 40,788 shares in the last quarter. FMR LLC grew its holdings in shares of Xencor by 315.5% in the third quarter. FMR LLC now owns 16,764 shares of the biopharmaceutical company's stock valued at $337,000 after acquiring an additional 12,729 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Xencor during the third quarter valued at approximately $205,000. Finally, Point72 Asia Singapore Pte. Ltd. lifted its holdings in Xencor by 8.5% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company's stock worth $244,000 after acquiring an additional 949 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.